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Abstract
Congenital heart disease (CHD) patients have increased prevalence of extra-cardiac congenital 
anomalies (CA) and risk of neurodevelopmental disabilities (NDD). Exome sequencing of 1,213 
CHD parent-offspring trios identified an excess of protein-damaging de novo mutations, especially 
in genes highly expressed in developing heart and brain. These mutations accounted for 20% of 
patients with CHD, NDD and CA but only 2% with isolated CHD. Mutations altered genes 
involved in morphogenesis, chromatin modification, and transcriptional regulation, including 
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multiple mutations in RBFOX2, an mRNA splice regulator. Genes mutated in other cohorts 
ascertained for NDD were enriched in CHD cases, particularly those with coexisting NDD. These 
findings reveal shared genetic contributions to CHD, NDD, and CA and provide opportunities for 
improved prognostic assessment and early therapeutic intervention in CHD patients.
Extra-cardiac congenital anomalies (CA, structural or functional anomalies that arise in 
utero) occur in approximately 13% of newborns with congenital heart disease (CHD), 
including 2% with a genetic syndrome, almost twice the prevalence observed in infants 
without CHD (1). Newborns with CHD are also at risk for the emergence of 
neurodevelopmental disorders (NDD), including cognitive, motor, social and language 
impairments. NDD occurs in 10% of all children with CHD and in 50% with severe CHD 
(2). Explanations to account for the high frequency of CA and NDD in CHD patients 
include embryonic circulatory deficits and stresses associated with post-natal therapeutic 
interventions (3), but these hypotheses remain unproven.
We sequenced exomes in 1,213 CHD trios, (probands and their unaffected parents) enrolled 
in the Pediatric Cardiac Genetics Consortium (PCGC) (4) or the Pediatric Heart Network 
(PHN) (5) after excluding CHD cases with clinically recognized genetic syndromes. 
Analyses included 353 previously reported CHD trios (6). We compared de novo mutations 
identified in CHD that occurred in isolation, or accompanied by CA, NDD, or both 
(phenotypes in Tables S1 and Database S1). Previously sequenced trios (n=900) from the 
Simons Foundation Autism Research Initiative Simplex Collection, each consisting of the 
unaffected parents and sibling of a child with autism spectrum disorder, served as control 
trios (7–9).
CHD and control probands were analyzed for de novo mutations (Databases S2–3). To 
evaluate the significance of mutation frequencies, we adapted a recently reported de novo 
expectation model (10) to assess mutation rates by variant class (synonymous, loss of 
function [LoF; e.g., nonsense, frameshift, canonical splice disruptions], or missense). We 
derived gene-based rates of de novo mutation from local sequence context, and adjusted by 
per-base coverage separately in case and control cohorts (Databases S4–5). We extended the 
model by merging all possible transcripts to obtain transcript-independent probabilities and 
by adding rates for deleterious missense variants predicted by the Meta-SVM score (D-Mis) 
(11). This yielded an overall mean expected mutation rate of 1.1 de novo variant per 
proband.
The expected and observed numbers of de novo mutations in each variant class in all CHD 
and control subjects (Table 1) were compared using a Poisson distribution. De novo 
mutation rates per variant class were accurately predicted in controls, replicating previous 
model validations (10). However, among all CHD trios, we detected significant enrichment 
(i.e., observed divided by expected frequencies) of LoF and D-Mis variants of 1.3 
(p=0.0016) and 1.6 (p=1.8×10−10), respectively, across all genes. The combination of LoF
+D-Mis variants (hereafter denoted as “damaging”) was 1.4-fold enriched in CHD cases 
compared to expectation, similar to the observed case vs. control comparison (Table S2). 
This burden persisted after excluding 353 previously studied CHD trios (Table S3) and was 
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found in each CHD category (conotruncal defects, left ventricular outflow tract obstruction 
and “other”), except for heterotaxy, which showed no excess (Table S4).
Damaging de novo mutations were markedly increased in CHD cases (enrichment=2.4, 
p=5.1×10−24) among 4,420 genes in the top quartile of expression during heart development 
(high heart expression, HHE (6)) (Table 1). Conversely, controls had no significant 
enrichment in de novo mutations in HHE genes. Neither cases nor controls were enriched in 
de novo mutations among genes within the lower three quartiles of developing heart 
expression (LHE) (Table 1). From the observed and expected values, we estimated that 58% 
of these damaging de novo mutations contributed to CHD.
Twenty-one genes had multiple damaging de novo mutations only in cases, an unlikely 
chance occurrence (Fig. 1A; median expected 7; p=1.1×10−5 by permutation), suggesting 
that these genes are likely to be pathogenic for CHD (Fig. 1B). Indeed, this list includes 
seven genes previously implicated in CHD (PTPN11, KMT2D, CHD7, MYH6, JAG1, 
NOTCH1, ZEB2). Enrichments were not observed among genes with multiple de novo 
synonymous variants in CHD cases or across any variant class among controls (Fig. 1A and 
Table S5). A variety of cardiac malformations were associated with mutations in each of 
these 21 genes (Fig 1B and Table S6). From simulations based on these data (12), we 
estimate that de novo mutations in ~392 HHE genes contribute to CHD pathogenesis (Fig. 
S1).
Within this 21-gene set, PTPN11, KMT2D (MLL2), and RBFOX2, each had significantly 
more damaging de novo mutations than expected (Bonferroni corrected threshold for 
genome-wide significance = p<9×10−7; Fig. 1B). RBFOX2, an RNA binding protein that 
regulates alternative splicing has not been previously implicated in CHD. RBFOX2 harbored 
three distinct de novo LoF mutations, a highly significant finding (Fig. 1B; p=3.4×10−8). 
Additionally, we previously identified a de novo copy number loss that encompasses 
RBFOX2 in another CHD proband (13). Remarkably, these four probands all have 
hypoplastic left heart syndrome (HLHS). RBFOX2 is critical for zebrafish heart 
development (14), and regulates epithelial-mesenchymal transitions (EMT) (15). Disruption 
of EMT is felt to underlie HLHS pathogenesis (16). Notably, we observed significant 
enrichment of damaging mutations in RBFOX2 target genes (17) in CHD cases (1.9-fold, 
p=6.6×10−8) but not controls (Table S7).
Gene ontology (GO) analysis revealed enrichment of damaging de novo mutations in genes 
involved in anatomic structure morphogenesis (GO:0009653; 2.4-fold; Bonferroni 
p=3.4×10−14), cardiovascular system development (GO:0072358; 3.2-fold; Bonferroni 
p=7.5×10−9), neurodevelopmental abnormality (HP:0012759; 2.6-fold; Bonferroni 
p=1.8×10−6), and others (Database S6). We replicated the reported excess of de novo LoF 
mutations affecting chromatin modification (6), even after including only newly studied 
cases (GO:0016568, 5.1-fold enrichment, p-value=7.2×10−5; Database S7). In the full CHD 
cohort, there were 25 de novo LoF mutations in chromatin modifying genes, a 5.3-fold 
enrichment over expectation (p=5.7×10−11, Table S8; Fig. S2), strongly supporting the 
conclusion that these damaging de novo mutations impart large effects on CHD risk.
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We examined the prevalence of damaging de novo mutations in CHD with or without NDD 
and/or CA (Fig 2A–C) after excluding 19 subjects found to have de novo mutations in 
known syndromic CHD genes and 279 subjects with uncertain NDD/CA status. Damaging 
de novo mutations in HHE genes were not significantly enriched in 356 subjects with 
isolated CHD nor in controls, but were ~3-fold enriched in 559 CHD cases with CA and/or 
NDD (CHD + Extra, p=1.1×10−18) including 97 probands diagnosed with either NDD or 
CA but unknown for the other phenotype. Excluding these 97 probands, we observed a 4.7-
fold enrichment of damaging de novo mutations in HHE genes among 138 CHD cases with 
both NDD and CA (p=5.6×10−15), a 2-fold enrichment in CHD cases with only NDD (252 
probands, p=3.8×10−4) and a 2.9-fold enrichment in CHD cases with only CA (72 probands, 
p=7.4×10−4). By comparing de novo rates in cases against expectation, we estimate that 
damaging de novo mutations in HHE genes contributed to 20% of CHD with both NDD and 
CA (95% confidence interval 12–30%), 10% (7–14%) of CHD with CA and/or NDD, 10% 
(2.5–23%) and 6% (2–11%) of CHD with CA or NDD only, respectively, and only 2% (0.5–
5%) of isolated CHD (Fig. 2B). These results implied frequent pleiotropic effects of de novo 
mutations in CHD and raise the possibility that mutations in these same genes might also 
contribute to non-syndromic NDD and/or other CA. Indeed, we find that genes mutated in 
CHD are not only enriched for high expression in developing heart, they are also enriched 
for high expression in developing brain (Table S9).
To further explore these pleiotropic effects, we considered whether genes with damaging de 
novo mutations in CHD with NDD overlapped with 1,161 genes (Database S8) found to 
contain damaging de novo mutations in seven cohorts ascertained for NDD phenotypes 
excluding CHD (published NDD, P-NDD gene set) (7, 18–23). Sixty-nine genes (Table S10) 
with damaging de novo mutations (n=85 mutations) were shared in CHD and P-NDD 
cohorts, far more than expected by chance (expected = 32 mutations; 2.6-fold enrichment; 
p=8.9×10−15, Fig. 3A and Table S19). HHE genes were particularly enriched among P-NDD 
genes that were mutated in CHD (4.4-fold for all CHD cases, p=1.2×10−23; Fig. 3A and 
Table S11). Moreover, genes mutated both in P-NDD and CHD cohorts are in the top 
quartile of both developmental heart and brain expression far more than expected by chance 
(observed = 38, expected = 11, p=6.1×10−11, binomial test, Fig. 3B). Input of these 69 
overlapping genes into GO ontology analysis revealed significant terms that were broadly 
involved in the regulation of developmental transcription programs. These included 19 
chromatin modifiers (GO:0016568 9.3-fold, p=8.5×10−10; Database S9 and Fig. S2) 
including genes responsible for altering the methylation, acetylation or ubiquitination status 
of numerous regulatory lysine residues on the nucleosome. Additionally, there were 32 
transcriptional regulators (GO:0006355 2.8-fold p=1.5×10−4; Database S9), including genes 
involved in the Wnt (CTNNB1, DVL3, LRP5) and Notch (NOTCH1, EP300) signaling, 
important pathways in cardiac development. These findings demonstrate shared genetic 
etiologies for CHD and NDD patients, and confirm pleiotropic effects of mutations in these 
genes. Because it is unlikely that many P-NDD-ascertained patients with these mutations 
had clinically important CHD, and not all CHD patients with these mutations have NDD 
(see below), our findings also indicate that these mutations have variable expressivity, 
including isolated CHD, isolated NDD, or both.
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Consistent with these observations, CHD subjects with damaging de novo mutations in these 
69 overlapping genes (Fig. 3A) had a significantly increased risk of NDD (absolute risk of 
73%, odds ratio 3.1, p=7.9×10−5, Fisher exact test). Damaging mutations (28 mutations in 
27 subjects) in chromatin modifiers showed the highest risk of NDD (19 subjects with NDD, 
8 with unknown NDD status due to age <1 year at evaluation). Moreover, the marked 
enrichments in damaging de novo mutations among P-NDD genes with HHE (Fig. 3A and 
Table S11), 7.4-fold in 413 CHD cases with NDD (p=3.9×10−22), 4.1-fold in 362 CHD 
infants with unknown NDD status (p=2.2×10−7) and no significant enrichment in 438 CHD 
cases without NDD (p=0.075), strongly implies a future risk of NDD among CHD infants 
with these variants. These observations suggest that genotype is a strong predictor for future 
development of NDD in CHD infants. Despite these highly significant findings, our 
estimates are based purely on statistical grounds and limited to in silico predictions of 
damaging variants, a caveat that should be considered when extrapolating these results to 
identify causative/predictive mutations in individual patients.
Contemporary therapeutic interventions have substantially improved survival among 
newborns with serious CHD. Despite these advances, many life-long medical issues remain. 
The demonstration that damaging de novo gene mutations cause CHD, particularly when 
associate with NDD and other birth defects has both clinical and research implications. First, 
clinical genotyping may help stratify CHD patients and identify those at high risk for NDD, 
enabling surveillance and early interventions to improve school performance, employability 
and quality of life. Second, the pleiotropic consequence of these mutations implies that 
further study of these genes may uncover critical regulation of broad developmental 
programs. Finally, the high frequency of mutation in transcriptional regulators suggests that 
mutations in regulatory elements (promoters and enhancers) may be additional causes of 
CHD, particularly isolated CHD.
Supplementary Material
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Fig. 1. 
Genes with multiple de novo mutations are candidate CHD risk genes. A: Histograms show 
the expected distribution of the number of genes containing multiple de novo mutations 
(empirically derived using 1M permutations, black), and the observed number of genes with 
multiple mutations in cases (red line) for each class. P-values were calculated by 
permutation. B: Twenty-one genes with multiple damaging de novo mutations in cases. P-
values are from Poisson test against expectation, with significance threshold < 9×10−7. 
Further details are shown in Table S6.
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Fig. 2. 
Burden of damaging de novo mutations in HHE genes among CHD cases with extra-cardiac 
phenotypes. A: The enrichment (ratio of observed/expected) of damaging de novo mutations 
in HHE genes is shown for each phenotype (± 95% confidence interval). Case probands 
were excluded if they carried de novo mutations in known CHD syndrome genes (n=19), 
had unknown extracardiac phenotype for both NDD and CA (n=6), or had one unknown 
phenotype and were negative for the other (n=273). Cases with either CA or NDD and 
unknown status for the other phenotype (n=97) were included in the “Extra” category but 
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excluded from the “only” categories. B: Percent excess of individuals carrying damaging de 
novo mutations in HHE genes by indicated phenotype (± 95% confidence interval). 
Explanation of calculation is provided (12). C: Table of observed and expected de novo rates 
for the indicated variant classes by phenotype.
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Fig. 3. 
Genes containing de novo mutations in CHD cases show pleotropic developmental effects. 
A: Individuals with CHD carry an excess of damaging de novo mutations among 1,161 
genes identified by containing damaging de novo mutations in 7 published studies of NDD 
(P-NDD cohort) (7, 18–23). All CHD cases were subdivided by NDD status (CHD + NDD, 
n=417 subjects, CHD – NDD n=440, Unknown NDD, n=363). P-values ≤ 0.005 as indicated 
(stars) were calculated from Poisson test against model-derived distribution (values in Table 
S11). P-NDD gene set (blue) was further filtered for HHE genes (P-NDD/HHE, red, 564 
genes). Enrichments are shown ± 95% confidence intervals. B: Percentile gene expression 
ranks (100=high) are shown for all genes (grey) in the developing brain and heart, 
highlighting 69 genes with damaging de novo mutations in both CHD cases and the P-NDD 
cohort (blue or purple). Genes with multiple de novo mutations in CHD (red or purple) are 
shown. Point size represents numbers of de novo events.
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